 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
36 News |  |
- || Cantrixil (TRX-E-002-1) / Oasmia
Clinical, P1 data, Journal: Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results. (Pubmed Central) - Jul 4, 2021
P1
The molecular target and mechanism of action of Cantrixil are yet to be confirmed. Preliminary analysis of stem cell markers suggests that IP Cantrixil might induce ovarian cancer stem cell death and sensitize cells to standard chemotherapy, warranting further evaluation.
- Cantrixil (TRX-E-002-1) / Oasmia
[VIRTUAL] TRX-E-002-1 in treatment-refractory ovarian cancer: Final phase 1 study results from the dose-escalation and dose-expansion cohorts (Channel 10) - Mar 11, 2021 - Abstract #AACR2021AACR_1307;
P1
IP-administered Cantrixil, a first-in-class, dual acting, anti-cancer therapy has encouraging activity in a cohort of difficult to treat patients with persistent epithelial ovarian, fallopian tube or primary peritoneal cancer who have demonstrated resistance to a range of prior treatments. Disease response compares favorably to a figure of 10% for historical controls.
- Cantrixil (TRX-E-002-1) / Kazia
TRX-E-002-1 in treatment-refractory ovarian cancer - 3-month follow-up results from a phase I study dose escalation phase (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_1809;
P1
Disease response compares favorably to a figure of 10% for historical controls. IP administered TRX-E-002-1 as a first-in-class, dual acting, anti-cancer therapy has preliminary activity for the treatment of platinum resistant ovarian cancer for patients who have demonstrated resistance to a range of prior treatments.
- || Cantrixil (TRX-E-002-1) / Vivesto
Trial completion, Trial primary completion date: Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. (clinicaltrials.gov) - Apr 20, 2020
P1, N=28, Completed, Sponsor: Kazia Therapeutics Limited
IP administered TRX-E-002-1 as a first-in-class, dual acting, anti-cancer therapy has preliminary activity for the treatment of platinum resistant ovarian cancer for patients who have demonstrated resistance to a range of prior treatments. Active, not recruiting --> Completed | Trial primary completion date: Dec 2019 --> Mar 2020
- | Cantrixil (TRX-E-002-1) / Kazia
Biomarker, Preclinical, Journal: Mechanism of action of the third generation benzopyrans and evaluation of their broad anti-cancer activity in vitro and in vivo. (Pubmed Central) - Sep 28, 2019
In this study, we investigated the mechanism of action of the third-generation benzopyran compounds, TRX-E-002-1 and TRX-E-009-1...This finding along with immunostaining, in vitro polymerization assays, and animal experiments in both athymic and immunocompetent mice, demonstrates that these third-generation benzopyran compounds are potent tubulin polymerization inhibitors in vitro and in vivo, and this is the molecular basis of their anti-cancer activity in melanoma. These findings indicate these BP compounds may offer a novel anti-microtubule strategy for cancer intervention and provides the basis for further investigation into biomarkers of clinical sensitivity.
- | Cantrixil (TRX-E-002-1) / Vivesto
Enrollment closed, Enrollment change, Trial completion date: Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. (clinicaltrials.gov) - Sep 15, 2019
P1, N=28, Active, not recruiting, Sponsor: Kazia Therapeutics Limited
These findings indicate these BP compounds may offer a novel anti-microtubule strategy for cancer intervention and provides the basis for further investigation into biomarkers of clinical sensitivity. Recruiting --> Active, not recruiting | N=60 --> 28 | Trial completion date: Dec 2019 --> Mar 2020
- Cantrixil (TRX-E-002-1) / Kazia
Phase I study of intraperitoneal TRX-E-002-1 in subjects with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer: Three-month follow-up results of the dose escalation phase (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2161;
P1
Clinical trial identification: NCT02903771. Legal entity responsible for the study: Kazia Therapeutics Limited.
- | Cantrixil (TRX-E-002-1) / Vivesto
Trial completion date, Trial primary completion date: Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. (clinicaltrials.gov) - Jul 24, 2018
P1, N=60, Recruiting, Sponsor: Kazia Therapeutics Limited
Legal entity responsible for the study: Kazia Therapeutics Limited. Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Oct 2018 --> Oct 2019
- Cantrixil (TRX-E-002-1) / Vivesto
Enrollment open: Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. (clinicaltrials.gov) - Dec 5, 2016
P1, N=60, Recruiting, Sponsor: Novogen Ltd
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Oct 2018 --> Oct 2019 Not yet recruiting --> Recruiting
- Cantrixil (TRX-E-002-1) / Vivesto
New P1 trial: Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. (clinicaltrials.gov) - Sep 16, 2016
P1, N=60, Not yet recruiting, Sponsor: Novogen Ltd